A new study provides real-world evidence to support the potential repurposing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), used to treat type 2 diabetes and obesity, for prevention of Alzheimer’s disease (AD). Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their peers who were prescribed any of...
Tag: <span>Semaglutide</span>
Post
Popular diabetes and weight-loss drug may reduce risk of Alzheimer’s disease
by Case Western Reserve University Credit: SHVETS production from Pexels Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D). Alzheimer’s disease is a brain disorder...
Post
How Are Doctors Using Tirzepatide vs Semaglutide? A Q&A
When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction. Studies indicated that tirzepatide can lead to greater weight loss than semaglutide. Factors like insurance coverage, drug availability, and side effects also influence physicians’ choices, with some patients...
Post
Semaglutide boosts heart health, weight loss but may lead to gut problems
Semaglutide drugs aid weight loss and heart health but does that come at the expense of gut health? Image credit: Douglas Cliff/Getty Images. The diabetes medication semaglutide — sold under brand names including Ozempic, Wegovy, and Rybelsus — which has also gained popularity as a weight-loss tool, has another significant health benefit, a new meta-analysis suggests. Only Wegovy has...
Post
Semaglutide a Potential Treatment Option for Opioid Use Disorder?
Medscape Medical News Eve Bender September 27, 2024 Semaglutide (Ozempic, Novo Nordisk) is associated with a significantly lower risk for overdose in individuals with opioid use disorder (OUD), new research shows. The findings suggest that the drug may be a promising treatment option for OUD, adding to the growing evidence of the potential psychiatric benefits...
Post
Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes
Credit: Unsplash/CC0 Public Domain Groundbreaking research presented at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy. This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy) with semaglutide, resulted in the elimination of insulin therapy for 86% of...
Post
Semaglutide improves outcomes for obese patients with common skin condition, new study shows
September 25, 2024 by European Academy of Dermatology and Venereology A pioneering study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity. This is the first study to explore the use...
Post
Combining Semaglutide and Mineralocorticoids May Improve CKD
Medscape Medical News > Conference News > EASD 2024 Nancy A. Melville September 19, 2024 MADRID — The benefits of semaglutide treatment in reducing kidney disease, cardiovascular, and mortality risks in people with type 2 diabetes and chronic kidney disease (CKD) are observed regardless of whether patients are also being treated with mineralocorticoid receptor antagonists...
Post
Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution
Medscape Medical News Megan Brooks August 20, 2024 A new analysis has detected a signal of suicidal ideation associated with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide, especially among individuals concurrently using antidepressants or benzodiazepines. However, the investigators and outside experts urge caution in drawing any firm conclusions based on the study’s observations....
Post
Semaglutide’s cardiovascular benefits are maintained in people with impaired kidney function, research finds
September 11, 2024 by Diabetologia Credit: Pixabay/CC0 Public DomainThe anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function, according to new research to be...